Does hypoxia and stress erythropoiesis compromise cardiac function in healthy adults? A randomized trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Does hypoxia and stress erythropoiesis compromise cardiac function in healthy adults? A randomized trial. / Arrebola-Moreno, Antonio L; Casuso, Rafael A; Bejder, Jacob; Bonne, Thomas Christian; Breenfeldt Andersen, Andreas; Aragón-Vela, Jerónimo; Nordsborg, Nikolai Baastrup; Huertas, Jesús R.
In: Sports Medicine - Open, Vol. 8, 137, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Does hypoxia and stress erythropoiesis compromise cardiac function in healthy adults? A randomized trial
AU - Arrebola-Moreno, Antonio L
AU - Casuso, Rafael A
AU - Bejder, Jacob
AU - Bonne, Thomas Christian
AU - Breenfeldt Andersen, Andreas
AU - Aragón-Vela, Jerónimo
AU - Nordsborg, Nikolai Baastrup
AU - Huertas, Jesús R
N1 - © 2022. The Author(s).
PY - 2022
Y1 - 2022
N2 - Objectives: To investigate whether recombinant human erythropoietin (rHuEPO) injections during an altitude training camp impact heart function.Methods: Thirty (12 women) moderately trained subjects stayed at 2320 m altitude for 4 weeks while training. Subjects were randomized to placebo (isotonic saline) or rHuEPO (20 IU/kg body weight) i.v. injections. Transthoracic echocardiography imaging was acquired 3 days after arrival to altitude and prior to the first placebo or rHuEPO injection as well as one day after the last rHuEPO injection three weeks later.Results: rHuEPO did not alter cardiovascular morphology parameters, systolic or diastolic function. In the placebo group, altitude exposure improved left ventricle (LV) systolic function due to an increased twist angle but rHuEPO had no additional effects. Pulmonary arterial systolic pressure was unaffected in either group. Notably, rHuEPO hampered LV untwist rate without affecting LV early filling.Conclusion: rHuEPO provided during mild altitude exposure does not cause any major effects on heart function. The observed alteration in LV untwist induced by rHuEPO is unlikely to have a meaningful clinical effect. Trial registration: Registered on www.clinicaltrials.gov (NCT04227665).
AB - Objectives: To investigate whether recombinant human erythropoietin (rHuEPO) injections during an altitude training camp impact heart function.Methods: Thirty (12 women) moderately trained subjects stayed at 2320 m altitude for 4 weeks while training. Subjects were randomized to placebo (isotonic saline) or rHuEPO (20 IU/kg body weight) i.v. injections. Transthoracic echocardiography imaging was acquired 3 days after arrival to altitude and prior to the first placebo or rHuEPO injection as well as one day after the last rHuEPO injection three weeks later.Results: rHuEPO did not alter cardiovascular morphology parameters, systolic or diastolic function. In the placebo group, altitude exposure improved left ventricle (LV) systolic function due to an increased twist angle but rHuEPO had no additional effects. Pulmonary arterial systolic pressure was unaffected in either group. Notably, rHuEPO hampered LV untwist rate without affecting LV early filling.Conclusion: rHuEPO provided during mild altitude exposure does not cause any major effects on heart function. The observed alteration in LV untwist induced by rHuEPO is unlikely to have a meaningful clinical effect. Trial registration: Registered on www.clinicaltrials.gov (NCT04227665).
KW - Faculty of Science
KW - Altitude
KW - Haematology
KW - Heart
KW - Doping
U2 - 10.1186/s40798-022-00531-x
DO - 10.1186/s40798-022-00531-x
M3 - Journal article
C2 - 36334130
VL - 8
JO - Sports Medicine - Open
JF - Sports Medicine - Open
SN - 2199-1170
M1 - 137
ER -
ID: 325010664